Domain Therapeutics announces nomination of first-in-class PAR2 NAM candidate, DT-9045, to unlock new cancer treatment possibilities
June 05, 2023 07:00 ET
|
Domain Therapeutics
Domain Therapeutics announces nomination of first-in-class PAR2 NAM candidate, DT-9045, to unlock new cancer treatment possibilities DT-9045 is a unique drug candidate due to its competitive...